{
    "organizations": [],
    "uuid": "959b4f591a7908d5862ab957711db21f304ffb03",
    "author": "",
    "url": "https://www.reuters.com/article/brief-merck-announces-first-phase-3-stud/brief-merck-announces-first-phase-3-studies-for-pcv-15-its-investigational-pneumococcal-disease-vaccine-idUSFWN1RU0U3",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17, 2018 / 12:33 PM / Updated 9 minutes ago BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine Reuters Staff \nApril 17 (Reuters) - Merck & Co Inc: \n* MERCK ANNOUNCES FIRST PHASE THREE STUDIES FOR PCV-15 (V114) ITS INVESTIGATIONAL PNEUMOCOCCAL DISEASE VACCINE \n* MERCK - FIRST STUDY TO EVALUATE PCV-15 FOLLOWED BY PNEUMOCOCCAL VACCINE POLYVALENT ONE YEAR LATER IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER \n* MERCK - SECOND PHASE 3 STUDY TO EVALUATE PCV-15 FOLLOWED BY PNEUMOCOCCAL VACCINE POLYVALENT GIVEN 8 WEEKS LATER IN ADULTS INFECTED WITH HIV Source text for Eikon: Further company coverage:",
    "published": "2018-04-17T15:33:00.000+03:00",
    "crawled": "2018-04-17T15:52:13.076+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "first",
        "phase",
        "study",
        "v114",
        "investigational",
        "pneumococcal",
        "disease",
        "vaccine",
        "reuters",
        "staff",
        "april",
        "reuters",
        "merck",
        "co",
        "inc",
        "merck",
        "announces",
        "first",
        "phase",
        "three",
        "study",
        "v114",
        "investigational",
        "pneumococcal",
        "disease",
        "vaccine",
        "merck",
        "first",
        "study",
        "evaluate",
        "followed",
        "pneumococcal",
        "vaccine",
        "polyvalent",
        "one",
        "year",
        "later",
        "healthy",
        "adult",
        "year",
        "age",
        "older",
        "merck",
        "second",
        "phase",
        "study",
        "evaluate",
        "followed",
        "pneumococcal",
        "vaccine",
        "polyvalent",
        "given",
        "week",
        "later",
        "adult",
        "infected",
        "hiv",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}